Cystic Fibrosis Drugmaker Nivalis Sets Terms For $64M IPO
Nivalis Therapeutics Inc., which is developing a clinical stage treatment for cystic fibrosis, set terms on Wednesday for an initial public offering that could raise as much as $64 million to...To view the full article, register now.
Already a subscriber? Click here to view full article